on VALNEVA (EPA:VLA)
Valneva Secures Exclusive Vaccine Distribution in Germany with CSL Seqirus
Valneva SE has announced an exclusive agreement with CSL Seqirus for marketing and distribution of its vaccines in Germany. Starting July 2025, CSL Seqirus will market Valneva’s chikungunya vaccine IXCHIQ®. By January 2026, they will also distribute IXIARO® for Japanese Encephalitis and DUKORAL® for cholera/ETEC1. This agreement replaces Valneva’s previous deal with Bavarian Nordic, concluding in December 2025.
The agreement spans three years with minimum purchase requirements. Valneva’s chief commercial officer highlighted CSL Seqirus's strong market presence, enhancing vaccine distribution efficiency in Germany. Valneva projects sales growth to €170-180 million in 2025, suggesting a positive financial outlook.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALNEVA news